

CHANGE # 2

### IR-4 PROTOCOL CHANGE FORM

**Project Title:** Quinoxifen/Hops

**PR No.:** 10084

**Field I.D. No.:** 10084.08-WA27

**Lab I.D. No.** 10084.08-CAR12

#### 1) Description of Amendment

Use of control samples from a source other than the field trial in this study is allowed.

#### Reason for Amendment:

There is a tight timeline for analyses of the samples from this study. The lab director has requested use of control samples from the Washington trial of V-10118/hops (trial 09190.06-WA16, samples A and/or B) in order to start method development and validation prior to the arrival of the samples from this study.

#### Impact on Study:

None. Adequate documentation is available on the source of the hops to be used as a control sample. Since the hops are also from Washington State, it is anticipated they will provide a good model for the hops generated in this study.

Control samples A and B will be collected from trial 10084.08-WA27 as specified in the protocol.

#### 2) Description of Amendment

In addition to the samples listed in Section 18 of the protocol, take the following additional treated samples at 28 days.

#### 18.0 FIELD RESIDUE SAMPLE INVENTORY:

SAMPLE ID	TRT#	TREATMENT	DAYS AFTER LAST APPLIC.	MINIMUM SAMPLE SIZE	CROP FRACTION
M	02	QUINOXYFEN	28 (+3)	1 lb.	Dry Cones
N	02	QUINOXYFEN	28 (+3)	1 lb.	Dry Cones

#### Reason for Amendment:

The study director has authorized shipment of samples K and L on dry ice via an overnight carrier (such as FedEx). Samples M and N are back up samples, in case samples K and L are lost en route to the laboratory. Once samples K and L have been received at the laboratory, and lab personnel have confirmed that the samples arrived frozen and in good condition, samples M and N will be discarded.

THIS PROTOCOL CHANGE FORM COPIED ON COLORED PAPER IS AN EXACT COPY OF THE ORIGINAL

**Impact on Study:**

This will provide back up samples if samples K and L are lost. The treated plot is large enough to take two extra samples, so taking extra samples will have no impact.

Authorization:

Deborah Carpenter September 9, 2008  
Study Director (DATE)

[Signature] 9/9/2008  
Sponsor (DATE)

cc: IR-4 QA Unit  
FRD: D. Groenendale  
RFC: R. Sisco  
LRD: M. Hengel